List of Excipients in Branded Drug LOPERAMIDE HYDROCHLORIDE 2MG

Generic Drugs Containing LOPERAMIDE HYDROCHLORIDE 2MG

Company	Ingredient	NDC	Excipient
MARKSANS PHARMA LIMITED	loperamide hydrochloride tablets usp, 2mg	25000-001	CARNAUBA WAX
MARKSANS PHARMA LIMITED	loperamide hydrochloride tablets usp, 2mg	25000-001	CELLULOSE, MICROCRYSTALLINE
MARKSANS PHARMA LIMITED	loperamide hydrochloride tablets usp, 2mg	25000-001	CROSCARMELLOSE SODIUM
MARKSANS PHARMA LIMITED	loperamide hydrochloride tablets usp, 2mg	25000-001	HYDROXYPROPYL METHYLCELLULOSE
MARKSANS PHARMA LIMITED	loperamide hydrochloride tablets usp, 2mg	25000-001	LACTOSE MONOHYDRATE
MARKSANS PHARMA LIMITED	loperamide hydrochloride tablets usp, 2mg	25000-001	MAGNESIUM STEARATE
MARKSANS PHARMA LIMITED	loperamide hydrochloride tablets usp, 2mg	25000-001	POLYETHYLENE GLYCOL

What are the Most Frequently-Used Excipients in LOPERAMIDE HYDROCHLORIDE 2MG?

# Of NDCs	Excipient
1	CARNAUBA WAX
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	HYDROXYPROPYL METHYLCELLULOSE
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL

Loperamide Hydrochloride 2 mg Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Loperamide hydrochloride 2 mg is a mature, low-cost antidiarrheal with limited opportunity at the active-ingredient level. Commercial differentiation is concentrated in excipient selection, dosage-form convenience, taste, packaging, pediatric usability, regulatory positioning, and supply reliability. The strongest opportunities are in orally disintegrating tablets, soft chews, liquid products, pharmacy and institutional packs, and abuse-resistant packaging rather than conventional immediate-release tablets.

What is the regulatory status of loperamide hydrochloride 2 mg?

Loperamide hydrochloride is an FDA-recognized antidiarrheal active ingredient available in prescription and nonprescription products. In the United States, loperamide is regulated under the FDA OTC monograph for antidiarrheal products, 21 C.F.R. § 333.520. The standard OTC dosage form is a 2 mg tablet, capsule, or equivalent oral dosage form.

FDA OTC labeling generally directs adults and patients 12 years and older to take 4 mg after the first loose stool, followed by 2 mg after each subsequent loose stool, with a maximum daily OTC dose of 8 mg under current Drug Facts labeling. Prescription labeling can permit higher daily dosing, subject to physician direction. Excessive use has been associated with serious cardiac adverse events, including QT prolongation, torsades de pointes, syncope, and cardiac arrest [1, 2].

FDA pathways

A new loperamide 2 mg product may use one of several regulatory routes:

Product type	Likely FDA pathway	Commercial implication
Prescription immediate-release tablet or capsule	ANDA or 505(b)(2), depending on formulation and reference product	Primarily price-driven
OTC tablet or capsule under monograph	OTC monograph compliance	Lower clinical development burden
Novel oral disintegrating tablet	OTC monograph or 505(b)(2), depending on claims and formulation	Opportunity for differentiated usability
Oral solution	OTC monograph or approved drug application	Pediatric and dysphagia opportunity
Combination product	Monograph or NDA pathway, depending on active ingredients and claims	Higher regulatory and formulation complexity
Institutional or pharmacy bulk pack	Existing approved or monograph route with packaging compliance	Supply-chain and procurement differentiation

The regulatory strategy should match the intended claim. A product marketed only for temporary control of nonspecific diarrhea has a simpler path than a product making pediatric, rapid-onset, sustained-release, or disease-specific claims.

What patents protect loperamide hydrochloride 2 mg products?

The original loperamide compound patent estate is expired. Loperamide was discovered and developed decades ago, and the basic compound, hydrochloride salt, and conventional immediate-release dosage concepts are no longer protected by meaningful U.S. composition-of-matter exclusivity.

The commercial patent question is therefore formulation-specific. A company may seek patents on:

• Orally disintegrating compositions
• Taste-masked liquid formulations
• Chewable tablets and soft chews
• Modified-release systems
• Multiparticulate dosage forms
• Abuse-resistant packaging or dose-limiting systems
• Specific excipient ratios
• Manufacturing processes that improve content uniformity or dissolution
• Stable liquid formulations
• Combination products containing loperamide and another active ingredient

These patents would protect a particular product architecture, not loperamide hydrochloride as a molecule.

How strong is the patent estate for loperamide 2 mg?

The baseline patent estate is weak because the active ingredient and conventional dosage forms are long genericized. A new formulation patent could have commercial value if it demonstrates a measurable technical effect, such as:

• Faster disintegration without excessive friability
• Improved palatability without reducing dissolution
• Stable loperamide concentration in an aqueous vehicle
• Reduced moisture sensitivity
• Improved dose uniformity at low fill weights
• Child-resistant unit-dose delivery
• A verified abuse-deterrent or dose-limiting feature

A patent based only on substituting one ordinary filler, binder, sweetener, or lubricant for another would face significant obviousness and enablement risk. Stronger claims would generally require defined composition ranges linked to reproducible performance data.

What excipients are suitable for loperamide hydrochloride 2 mg tablets?

A conventional immediate-release tablet can use a standard direct-compression or wet-granulation platform. The formulation must control low-dose content uniformity because the active load is small relative to the total tablet mass.

Conventional immediate-release tablet

Typical excipient classes include:

Function	Candidate excipient classes	Formulation purpose
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Builds tablet mass and supports compression
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force
Sweetener	Sucralose, saccharin sodium, aspartame, acesulfame potassium	Supports chewable or orally disintegrating formats
Flavor	Mint, berry, citrus, vanilla, or other taste systems	Masks bitterness
Film former	Hypromellose, polyvinyl alcohol	Improves appearance and handling
Opacifier	Titanium dioxide or alternative approved opacifiers	Controls appearance and light exposure

Microcrystalline cellulose is a practical filler for conventional tablets because it supports direct compression and acceptable mechanical strength. Mannitol is more attractive for orally disintegrating and chewable formats because it provides a cooling mouthfeel and lower perceived heaviness than some other fillers.

Lactose can be cost-effective but may interact with certain flavor systems or create tolerability concerns for selected users. Calcium phosphate can produce hard, stable tablets but may be less suitable for fast-disintegrating products.

What excipients are best for orally disintegrating loperamide tablets?

An orally disintegrating tablet, or ODT, is one of the clearest formulation opportunities for loperamide 2 mg. The format addresses patients who have difficulty swallowing during acute gastrointestinal illness and supports pharmacy-counter differentiation.

A practical ODT platform may combine:

• Mannitol as the principal filler
• Crospovidone or croscarmellose sodium as the disintegrant
• Low-substitution hydroxypropyl cellulose or another dry binder
• Colloidal silicon dioxide for flow
• Magnesium stearate or sodium stearyl fumarate at a controlled level
• Sucralose or acesulfame potassium for sweetness
• A strong flavor system to mask loperamide bitterness

The critical technical parameters are disintegration time, friability, tensile strength, moisture uptake, dissolution, taste, and tablet robustness during packaging and transport.

ODT patentability

An ODT patent is more defensible when the product combines a narrow excipient range with data showing a technical result. Potential claim themes include:

• Disintegration within a specified time at a defined tablet hardness
• Improved taste without delaying loperamide dissolution
• Low-moisture processing and packaging
• Reduced friability in a high-mannitol matrix
• A particular granulation or compression process
• Stability under accelerated and long-term conditions

A generic ODT should avoid relying on a single excipient substitution as its primary differentiation. The stronger commercial position comes from an integrated formulation and packaging system.

What excipients are suitable for loperamide oral liquids?

Liquid loperamide products can address dysphagia, institutional use, and selected pediatric markets. They also create greater formulation risk than tablets because loperamide hydrochloride must remain chemically and physically stable in an aqueous vehicle while maintaining acceptable taste.

Potential excipient categories include:

• Purified water
• Cosolvents such as glycerin or propylene glycol, subject to regulatory and age-specific limits
• Sorbitol or other bulk sweeteners
• Sucralose, saccharin sodium, or acesulfame potassium
• Buffer systems for pH control
• Chelating agents where justified by stability data
• Preservatives for multidose packaging
• Suspending or viscosity-modifying agents if the product is a suspension
• Flavor systems compatible with the selected pH and preservative system

A clear solution may be commercially attractive because it offers dose flexibility and easy administration. A suspension may provide an alternative where solubility, taste, or stability makes a solution impractical.

Liquid formulation barriers

The main barriers are:

1. Dose uniformity through the bottle life.
2. Chemical stability during storage.
3. Microbial control in multidose packaging.
4. Bitter taste and aftertaste.
5. Accurate dosing at the 2 mg dose level.
6. Compatibility between flavor, preservative, buffer, and container closure.
7. Age-specific excipient restrictions.

Unit-dose cups, oral syringes, or stick packs can reduce dosing errors and improve institutional handling. A preservative-free unit-dose product may command a premium if the formulation and packaging support the claim.

What commercial opportunities exist for loperamide hydrochloride 2 mg?

The opportunity is not broad molecule substitution. It is targeted product segmentation.

1. Orally disintegrating tablets

ODTs can compete on swallowing convenience, rapid disintegration, and portability. The product is suitable for OTC retail, travel health, convenience stores, and e-commerce.

2. Soft chews

Soft chews can improve acceptability for users who dislike tablets. The technical challenge is maintaining dose uniformity and controlling moisture migration. Sugar-free systems may expand use among consumers avoiding sucrose.

3. Taste-masked liquids

A palatable liquid can address dysphagia and institutional administration. The product requires careful control of bitterness, viscosity, preservative performance, and dosing accuracy.

4. Unit-dose and travel packaging

Blister packs, stick packs, and unit-dose cups can support:

• Travel retail
• Workplace first-aid kits
• Hospital and nursing-home procurement
• Emergency preparedness kits
• Pharmacy adherence and dose-control programs

Packaging also has a safety role because FDA has warned about intentional high-dose loperamide misuse [2].

5. Pediatric positioning

Pediatric use requires careful regulatory and clinical review. The commercial opportunity is strongest in age-appropriate dosage delivery, such as measured liquid or unit-dose formats, rather than simply reducing an adult tablet size. Claims must remain consistent with the applicable FDA labeling and safety restrictions.

6. Institutional products

Hospitals, long-term-care facilities, and pharmacies may value:

• Unit-dose packaging
• Barcoded inventory
• Tamper-evident closures
• Oral syringes
• Stable room-temperature products
• Low-cost bulk procurement
• Clear administration instructions

7. International private-label products

Loperamide is suitable for private-label and contract-manufacturing models because the active ingredient is established, widely available, and supported by mature analytical methods. Geographic opportunities depend on local monograph requirements, labeling rules, excipient permissions, and registration status.

What formulation patents could protect a new loperamide product?

A commercially meaningful patent program could be organized around four claim groups.

Composition claims

These cover defined ratios of loperamide hydrochloride and excipients, such as a fast-disintegrating matrix, taste-masked granules, or stable liquid system.

Performance claims

These claim a product that meets specified dissolution, disintegration, stability, or dose-uniformity criteria. Performance claims require robust analytical support and must be drafted carefully to avoid indefiniteness.

Process claims

These may cover:

• Ordered mixing
• Wet or dry granulation
• Spray drying
• Taste-masking coating
• Low-shear blending
• Moisture-controlled compression
• Multiparticulate manufacture

Process claims can create manufacturing barriers even when composition claims are narrow.

Packaging claims

Packaging claims may cover child-resistant, unit-dose, tamper-evident, or dose-limiting configurations. Packaging patents are most useful when they solve a specific safety, stability, or compliance problem.

When does loperamide lose exclusivity?

Loperamide has already lost U.S. small-molecule exclusivity. The original compound and conventional 2 mg products are long past their patent terms. The relevant exclusivity for a new entrant is product-specific:

Exclusivity category	Relevance to loperamide
Original composition patent	Expired
Conventional tablet or capsule patent	Expired or commercially obsolete
New formulation patent	Possible if a novel product is developed
New chemical entity exclusivity	Not available for established loperamide
Three-year clinical investigation exclusivity	Possible only for a qualifying new application and new clinical investigations
Orphan-drug exclusivity	Generally not applicable to standard antidiarrheal use
OTC monograph protection	Regulatory framework, not molecule-specific patent exclusivity

A new formulation may obtain patent protection, but it would not prevent competitors from selling conventional loperamide products outside the patented formulation scope.

What is the Orange Book status of loperamide?

The FDA Orange Book primarily identifies approved drug products, therapeutic equivalents, patents, and exclusivity information for prescription and certain approved products. Standard OTC monograph loperamide products do not receive the same Orange Book patent-listing treatment as an innovative prescription product.

For an approved prescription loperamide product, any listed patents would need to be assessed through the FDA Orange Book and the relevant approved labeling. For an OTC monograph product, the principal regulatory analysis is compliance with the monograph, labeling, manufacturing controls, and applicable drug-listing requirements rather than an Orange Book patent challenge.

Which companies compete in loperamide 2 mg?

Competition includes branded OTC products, national generic manufacturers, private-label suppliers, contract manufacturers, and regional consumer-health companies. The principal branded reference is Imodium, historically associated with Johnson & Johnson and later consumer-health portfolio ownership changes. Generic loperamide products are sold by multiple manufacturers and retailers under store brands.

The competitive variables are:

• Retail price
• Brand recognition
• Tablet, capsule, liquid, or chewable format
• Pack size
• Blister or bottle presentation
• Onset and usability claims permitted by labeling
• Taste and swallowability
• Pharmacy and wholesale distribution
• Supply reliability
• Private-label economics

Because the active ingredient is commoditized, a new entrant should target a defined channel or user problem rather than compete solely on tablet price.

Are Paragraph IV challenges relevant to loperamide?

Paragraph IV litigation is relevant only where a product applicant seeks approval of a generic or follow-on product that references an approved drug application with listed patents. For conventional loperamide hydrochloride 2 mg products, the practical Paragraph IV risk is limited because the foundational patent estate has expired and standard products are generally available through generic or OTC pathways.

A Paragraph IV strategy could arise for a newly patented formulation, such as:

• An ODT
• A modified-release product
• A stable oral solution
• A combination product
• An abuse-deterrent delivery system

The litigation risk would center on claim construction, obviousness, written description, enablement, and infringement of manufacturing or formulation claims. A company entering with a non-infringing conventional tablet may avoid the protected formulation while competing against it.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate for standard tablets and higher for differentiated formats.

Standard tablets

The main risks are low-dose content uniformity, powder segregation, compression variability, dissolution control, and supply continuity for the active ingredient.

ODTs and chews

The main risks are moisture sensitivity, friability, taste masking, compression-window limitations, and packaging performance.

Liquids

The main risks are solubility, precipitation, preservative efficacy, microbial control, pH stability, and dosing accuracy.

IP barriers

The most credible barriers may come from:

• Narrow formulation patents
• Taste-masking technology licenses
• ODT manufacturing platforms
• Specialized packaging patents
• Proprietary flavor systems
• Contract-manufacturing know-how
• Drug-device combinations involving dosing systems

A freedom-to-operate review should cover U.S., European, Canadian, Australian, Japanese, and major emerging-market filings because formulation and packaging patents may have different expiration dates and legal status by jurisdiction.

How does loperamide compare with competing antidiarrheal products?

Product	Primary mechanism	Typical differentiation	Excipient opportunity
Loperamide 2 mg	Peripheral opioid-receptor agonist that slows intestinal motility	Strong established OTC recognition	ODT, liquid, chewable, unit-dose, taste masking
Bismuth subsalicylate	Antisecretory, antimicrobial, and anti-inflammatory effects	Broad indigestion and diarrhea positioning	Suspension stability, flavor, sedimentation control
Diphenoxylate/atropine	Prescription antidiarrheal	Prescription channel and controlled-use positioning	Tablet and liquid delivery, physician-directed use
Oral rehydration solution	Replaces fluids and electrolytes	Dehydration management	Flavor, osmolarity, powder sachets, ready-to-drink packaging

Loperamide has the clearest opportunity for low-cost convenience formats. Bismuth products compete more directly on broad gastrointestinal symptom coverage, while oral rehydration products address the underlying fluid-loss risk rather than intestinal motility alone.

What generic launch scenarios exist for loperamide 2 mg?

Low-cost conventional launch

A standard tablet or capsule can enter through an established generic or OTC route. This strategy minimizes development costs but exposes the product to rapid price competition.

Premium convenience launch

An ODT, chewable, or liquid can support higher retail pricing if the format solves a clear administration problem. The product needs differentiated packaging and a credible user benefit.

Private-label launch

Retailers can use a contract manufacturer to sell store-brand loperamide in standard or differentiated formats. The key commercial controls are cost per dose, fill-rate reliability, and retail shelf placement.

Institutional launch

Unit-dose products can target hospitals and long-term-care facilities. Procurement advantages may matter more than consumer branding.

Geographic expansion

A manufacturer can use a common formulation platform across markets while adapting:

• Active-ingredient labeling
• Maximum daily dose
• Age restrictions
• Excipient permissions
• Package size
• Warning language
• Registration pathway

Key Takeaways

• Loperamide hydrochloride 2 mg is a mature generic active with no meaningful foundational U.S. composition-of-matter exclusivity.
• Conventional tablets and capsules are primarily price-competitive.
• The strongest commercial opportunities are ODTs, soft chews, palatable liquids, unit-dose packs, and institutional products.
• Excipient selection should prioritize content uniformity, rapid disintegration, taste masking, stability, and moisture control.
• New patents should focus on defined formulation systems, manufacturing processes, performance outcomes, or packaging technologies.
• FDA OTC monograph compliance is central for nonprescription products; Orange Book and Paragraph IV analysis is more relevant to approved prescription or newly patented reference products.
• High-dose misuse and cardiac safety concerns make dose-limiting packaging, clear labeling, and controlled pack sizes commercially relevant.
• A differentiated loperamide product should target usability and channel economics, not simply substitute one conventional filler for another.

FAQs

Can loperamide hydrochloride 2 mg be formulated as a sugar-free chewable?

Yes. Mannitol, xylitol, sorbitol, and high-intensity sweeteners can support sugar-free chewable systems. The formulation must control hygroscopicity, texture, dose uniformity, and the bitter aftertaste of loperamide.

Is an alcohol-free loperamide liquid commercially attractive?

Yes. An alcohol-free liquid can address consumer preferences, institutional requirements, and selected age-group considerations. Its feasibility depends on solubility, preservation, pH, taste masking, and container-closure compatibility.

Can a loperamide product use an oral syringe?

Yes. An oral syringe is suitable for a liquid product where accurate low-volume dosing is required. The package should be designed to minimize confusion between milligrams and milliliters.

Can excipients reduce loperamide abuse risk?

Excipients alone are unlikely to eliminate abuse risk. A safer strategy combines dose-limited packaging, restricted pack sizes, clear warnings, tamper-evident presentation, and, where technically justified, a formulation or delivery system that limits rapid ingestion.

Is a loperamide 2 mg product suitable for 505(b)(2) development?

A 505(b)(2) pathway may be relevant for a novel dosage form, delivery system, or formulation that cannot rely entirely on an ANDA or OTC monograph pathway. The commercial benefit depends on the strength of the formulation differentiation, required clinical data, and resulting patent or regulatory exclusivity.

References

1. U.S. Food and Drug Administration. (2023). Imodium A-D loperamide hydrochloride tablet: Drug facts and labeling. DailyMed.

2. U.S. Food and Drug Administration. (2016). FDA warns about serious heart problems with high doses of the anti-diarrheal medicine loperamide (Imodium), including doses higher than recommended. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-heart-problems-high-doses-anti-diarrheal-medicine-loperamide-imodium

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. Electronic Code of Federal Regulations. (2024). 21 C.F.R. § 333.520: Antidiarrheal active ingredients. https://www.ecfr.gov/

5. U.S. Food and Drug Administration. (2024). Drug approval package and labeling resources for loperamide hydrochloride products. https://www.accessdata.fda.gov/